StockData
Harmony Biosciences Holdings, Inc. logo

Harmony Biosciences Holdings, Inc. (HRMY) stock

HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 18/3039% below fair value
$33.11+0.10 (+0.30%)

Close on Nov 18, 2026Market cap $1.93BP/E 10.7Yield –

Harmony Biosciences pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Harmony Biosciences's pe ratio was 11.1× on Nov 11, 2026, against 11.1× a year earlier. Over the last 5 years it ranged from 7.2× to 213.3×, with a median of 13.2×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202611.1×−0.7
2025Dec 31, 202511.8×−4.5
2024Dec 31, 202416.3×+3.2
2023Dec 29, 202313.1×−8.4
2022Dec 30, 202221.5×−191.8
2021Dec 31, 2021213.3×–

More Harmony Biosciences figures

See a number that looks wrong?